Ceftolozane/tazobactam in action: Prescribing patterns, effectiveness, and healthcare utilisation across seven countries

This publication has 26 references indexed in Scilit:

• A real-world investigation into prescribing patterns and effectiveness of ceftolozane/tazobactam among critically ill patients from SPECTRA
  Diagnostic Microbiology and Infectious Disease, 2025
• Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis (SPECTRA)
  Journal of Global Antimicrobial Resistance, 2025
• Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
  The Lancet, 2024
• Current Treatment Strategies Against Multidrug-Resistant Bacteria: A Review
  Current Microbiology, 2022
• Long-term outcome and risk factors for late mortality in Gram-negative bacteraemia: a retrospective cohort study
  Journal of Global Antimicrobial Resistance, 2021
• Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
  The Lancet Infectious Diseases, 2019
• Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
  The Lancet, 2015
• Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study
  The Lancet, 2012
• Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study
  European Journal of Clinical Microbiology & Infectious Diseases, 2011
• Guidelines for good pharmacoepidemiology practices (GPP)
  Pharmacoepidemiology and Drug Safety, 2008